drugset / Trial / NCT02182544

WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis

NCT02182544

Phase 3 Completed 151 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate the efficacy of WAL801CL Dry Syrup in comparison with ketotifen fumarate on pediatric perennial allergic rhinitis and to evaluate the safety of WAL801CL Dry Syrup compared to ketotifen fumarate and to confirm the appropriateness of dosage of WAL801 Dry Syrup.

Timeline

Start
2001-06
Primary completion
2001-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinastine Small molecule
Comparator Ketotifen Small molecule